Zoetis (ZTS) Stock Still Looks Below Fair Value As Diagnostics Focus Builds

Zoetis stock has gone through a steep reset over the past few years, yet the broader valuation checks now suggest the shares may be pricing in more pessimism than the fundamentals warrant. After a long stretch of weak returns, the current market multiples and a strong value score point toward an undervalued animal health business rather than a crowded defensive trade.

• Over the past 5 years, Zoetis has declined about 62%, which signals that investor expectations around the animal health leader have cooled sharply.
• Fresh attention on veterinary diagnostics, highlighted in a recent industry report that profiles Zoetis as a key player, can support sentiment on longer term earnings power, while any disappointment in pet care spending or clinic investment would weigh on what investors are willing to pay for that potential.
• On Simply Wall St's broader checks, Zoetis scores a high 5 out of 6 on value, which leans toward the stock trading on the cheap side rather than looking fully priced.

The key question now is whether the current share price, given its exposure to veterinary diagnostics and wider animal health markets, still leaves enough potential upside to justify investing after such a long drawdown.

Compare Zoetis' reset with other potential undervalued opportunities by scanning the hand-picked 33 high quality undervalued stocks that share strong fundamentals and more conservative market expectations.

Does Zoetis Look Undervalued on Earnings?

The P/E ratio is a useful shortcut for Zoetis because earnings are a central driver of how investors judge the animal health group.

Zoetis currently trades on a P/E of about 11.4x, which sits well below both the Pharmaceuticals industry average of roughly 16.0x and a peer group average near 30.7x. The fair P/E multiple implied by broader checks is about 21.8x, so the market price is embedding a material discount to what those models suggest could be reasonable for a business with Zoetis' profile.

Fresh attention on veterinary diagnostics, including Zoetis' positioning in the recent Veterinary Diagnostic Markets report, comes against a backdrop where the P/E still lags sector and peer benchmarks. That combination points to sentiment that remains cautious compared with what the valuation framework implies.

On the P/E multiple alone, Zoetis appears undervalued relative to both its fair ratio and wider pharmaceutical peers.

See what the numbers say about this price — find out in our valuation breakdown.

The Zoetis Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Zoetis' valuation puzzle leaves off. Each one spells out the specific mix of growth, profitability and risk that would need to play out for Zoetis' current price to end up looking too low or too high. Every scenario links its number to a clear view on how revenue, margins and uncertainties might evolve, so you can return to those assumptions when new information comes through.

One of the top community narratives on Zoetis: 22% undervalued

"There’s hints of genuine value in the position but I figured there wouldn’t be enough people interested in their single-digit growth..."

Read one of the top narratives on Zoetis

Do you think there's more to the story for Zoetis? Head over to our Community to see what others are saying!

The Bottom Line

Zoetis screens as undervalued on market multiples, especially against sector benchmarks. However, the discount only matters if earnings resilience and diagnostic demand hold up. The valuation gap reflects hesitation about how much investors should pay for steadier animal health exposure compared with faster growing pharmaceutical peers. The crux from here is simple. Either the market eventually assigns a richer P/E to Zoetis' cash generation and diagnostics footprint, or current pricing proves to be the right answer if growth, margins or clinic spending underwhelm expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com